ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2020

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

Giancarlo Comi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.